Article citationsMore>>

Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J. and Lane, R. (2005) Rivastigmine and Donepezil Treatment in Moderate to Moderately-Severe Alzheimer’s Disease over a 2-Year Period. Current Medical Research & Opinion, 21, 1317-1327.
http://dx.doi.org/10.1185/030079905X56565

has been cited by the following article:

• TITLE: Prevalence of Wild-Type Butyrylcholinesterase Genotype in Patients with Alzheimer’s Dementia

  AUTHORS: Beate Mueller, Georg Adler

  KEYWORDS: Butyrylcholinesterase, Alzheimer’s Disease, Genotype

  JOURNAL NAME: World Journal of Neuroscience, Vol.5 No.3, June 2, 2015

  ABSTRACT: Approximately, two-thirds patients with Alzheimer’s disease (AD) are reported to have homozygous wild-type butyrylcholinesterase (BuChE) gene expression. It is associated with a higher rate of hydrolysis of acetylcholine, which ultimately leads to increase in the levels of BuChE in advanced stages of the disease. Rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and BuChE, might be of additional benefit in patients with AD with wild-type BuChE allele.